Overall management of Correctseq with focus in pipeline development, business development, fund raising and general operation. Directly report to the board. Explore new technologies, therapeutic targets and applications with academia groups, hospitals, business partners and venture capitals.Correctseq is a clinical stage biotechnology company leading evolution of new gene editing technologies with special focus on base editing. The mission of Correctseq is to develop breakthrough therapies by providing precision medicine towards permanent cure of patients with rare and common diseases in hematology, metabolism, infection, oncology and ophthalmology. A transformer base editor (tBE) with ultra-high editing precision and no off-target mutation has been IP authorized by US (original PCT), China and Australia, which was solely owned by Correctseq with exclusive rights globally. The IP are advancing globally in 15 top-tier regions. Pipelines of various therapeutic indications have been set up in ex-vivo cell therapy (stem cell and T cell) and in vivo (mRNA in LNP/AAV) platforms to benefit patients. The first pipeline for beta-hemoglobinopathies will achieve the completion of PhI clinical trial by end of 2024, and initiate pivotal clinical trial in 2025. Other IND enabling pipelines for obesity correlated metabolism diseases are under NHM study where long-term safety and efficiency have already been proven. Correctseq is open for collaboration with global partners in target screening, CMC platform and pipeline licensing out, and clinical co-development by region.

Expert in IFPMA-ICH-Cell and Gene Therapies Discussion Group (CGTDG)

Head of Microbial and Viral Platforms (MVP). Built up CDMO service in microbial fermentation and viral product with full responsibility for P&L. Towards enabling preventive and therapeutic vaccine, gene therapy and rare disease. Form full set of technical and operation team, set up new technology and manufacturing platform covering discovery, CMC and commercialization. Provide end-to-end service to global clients.

Centralize Resource Management, Procurement, Customs Affair, Logistics; oversee global supply chain operation of all sites of WuXi Biologics in Asia, Europe and US; set up global operation teams, minimize OP HC increase and control operation cost while accommodate fast business growth; close monitor policy updates from government agencies, provide in-time assessment to the impacts on domestic operation and global supply chain, propose solutions to the executive committee and lead execution.

Led Project Management Department to oversee hundreds of projects in WuXi Biologics from drug discovery, clone selection, process development, scale up tech transfer, clinical manufacturing, process characterization and validation, and commercial MFG to support IND and BLA filings and commercialization worldwide (US, EU, China, Australia, Singapore and Korea); worked closely with BD to cover hundreds of clients worldwide including all types of biotech startups and brand name pharmaceutical companies, maintain client relationship and develop new clients. Initiated ELITE program to recruit fresh PhDs worldwide for global talent development and reservation; Represented company during client visit, government tour and regulatory agent auditing (as the room master in the first PLI auditing of Biologics from US FDA in China).

Director in QC and CMC leader for integrated IND enabling projects for global clinical development

Analytical Team Lead in the Biologics-New and Enabling Technology group to support Biologics in-process development. DSP (Drug substance/product) project manager for in-pipeline Biologics.